ArticleNature methods2018
A light-gated potassium channel for sustained neuronal inhibition.
Article in Nature methods, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Neuromodulation Techniques Alleviating Neuropathic Pain by Targeting Microglia: A Narrative Review.Pain and therapy · 2026Review
- Zebrafish as a Model for Cardiovascular Disease Using Nanotechnology and Emerging Optogenetic Tools.Biomedicines · 2026Review
- Light-induced analgesia provides a drug-free optical method for pain relief via activation of TRAAK kNature communications · 2026Article
- Article
- Two Decades of Optogenetic Tools: A Retrospective and a Look Ahead.Advanced genetics (Hoboken, N.J.) · 2025Review
- Modular architecture of KEMBO reports · 2025Review
- Engineering plant photoreceptors towards enhancing plant productivity.Plant molecular biology · 2025Review
- Optogenetic engineering for ion channel modulation.Current opinion in chemical biology · 2025Review
- Suppression of epileptic seizures by transcranial activation of KNature communications · 2025Article
- Review
- Development of covalent chemogenetic KCell chemical biology · 2024Article
- Kalium channelrhodopsins effectively inhibit neurons.Nature communications · 2024Article
- Looking for a Beam of Light to Heal Chronic Pain.Journal of pain research · 2024Review
- Development of covalent chemogenetic KbioRxiv : the preprint server for biology · 2023Article
- Training-induced circuit-specific excitatory synaptogenesis in mice is required for effort control.Nature communications · 2023Article
- Review
- Optogenetics at the presynapse.Nature neuroscience · 2022Review
- Optophysiology: Illuminating cell physiology with optogenetics.Physiological reviews · 2022Review
- Kalium channelrhodopsins are natural light-gated potassium channels that mediate optogenetic inhibition.Nature neuroscience · 2022Article
- Conjugated microporous polymer membranes for light-gated ion transport.Science advances · 2022Article
Corrections and comments
- Commented on byAnna Moroni.2018
- Commented on by
Authors and funding
28 authors.
Funding
Abstract
Currently available inhibitory optogenetic tools provide short and transient silencing of neurons, but they cannot provide long-lasting inhibition because of the requirement for high light intensities. Here we present an optimized blue-light-sensitive synthetic potassium channel, BLINK2, which showed good expression in neurons in three species. The channel is activated by illumination with low doses of blue light, and in our experiments it remained active over (tens of) minutes in the dark after the illumination was stopped. This activation caused long periods of inhibition of neuronal firing in ex vivo recordings of mouse neurons and impaired motor neuron response in zebrafish in vivo. As a proof-of-concept application, we demonstrated that in a freely moving rat model of neuropathic pain, the activation of a small number of BLINK2 channels caused a long-lasting (>30 min) reduction in pain sensation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.